Most stocks in the industry cooled off from all-time highs. Will they keep sliding?
News & Analysis: Genomic Health
Since the start of September, the luster has disappeared from Exact Sciences' stock. This pullback provides an opportunity to own a company that is growing on multiple levels.
Exact Sciences takes out the cancer-test maker for $2.8 billion.
It was a great month to be a genetic testing company.
GHDX earnings call for the period ending June 30, 2019.
Shares are heading in opposite directions after the two cancer diagnostic companies surprised Wall Street by revealing plans to merge. Here's what investors need to know.
It had nothing to do with the underlying value of the company.
Invest for the long term with these three stocks.
Wall Street soured on the high-growth industry after first-quarter earnings were reported, but it may have been an overreaction for two stocks.
These companies could make a big difference in how the disease is diagnosed and treated. And their stocks could make a big difference for long-term investors.